nach oben

Tipp

A case report on the long-term survival of a patient with HER2-positive metastatic gastric adenocarcinoma and a short review of the current literature

Zeitschrift:: memo - Magazine of European Medical Oncology

Autoren:: MD Hannah Christina Puhr, MD PhD Aysegül Ilhan-Mutlu

» Zum Volltext PDF-Version jetzt herunterladen

Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

The prognosis of patients with metastatic gastroesophageal cancer remains poor despite numerous promising clinical trials, and the clinical benefit of systemic therapies is under critical review. This case report of a patient with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma is an impulse for the importance of individual decision making and molecular guided treatment options.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Jetzt informieren

Al-Batran S‑E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1. CrossRefPubMed

Tong G, Li S, Lin L, He L, Wang L, Lv G, et al. Trastuzumab with FLOT regimen for the perioperative treatment of resectable HER2 + advanced gastric cancer: a retrospective study. Cancer Manag Res. 2020;12:2481–9. https://doi.org/10.2147/CMAR.S239420. CrossRefPubMedPubMedCentral

Hofheinz R, Hausen GZ, Borchert K, Kretzschmar A, Ebert MP, Ettrich TJ, et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: petrarca—A phase II trial of the German AIO. J Clin Oncol. 2017;35(15_suppl):TPS4133. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS4133. CrossRef

Group G, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37. https://doi.org/10.1001/jama.2010.534. CrossRef

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/s0140-6736(10)61121-x. CrossRefPubMed

Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, et al. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer. 2016;16:68. https://doi.org/10.1186/s12885-016-2092-9. CrossRefPubMedPubMedCentral

Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372–84. https://doi.org/10.1016/S1470-2045(18)30481-9. CrossRefPubMed

Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2‑positive advanced or metastatic gastric, esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A randomized phase III trial. J Clin Oncol. 2016;34(5):443–51. https://doi.org/10.1200/jco.2015.62.6598. CrossRefPubMed

Lopez A, Chen H‑C, Harada K, Murphy MAB, Rogers JE, Thomas I, et al. Maintenance therapy with trastuzumab +/− fluoropyrimidine in non-progressive HER‑2 positive advanced gastroesophageal cancer patients after first-line chemotherapy. J Clin Oncol. 2018; https://doi.org/10.1200/JCO.2018.36.15_suppl.e16071. CrossRefPubMedPubMedCentral

10.

Fu X, Zhang Y, Yang J, Qi Y, Ming Y, Sun M, et al. Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer. OTT. 2018;11:6091–100. https://doi.org/10.2147/OTT.S174138. CrossRef

11.

Ilhan-Mutlu A, Taghizadeh H, Beer A, Dolak W, Ba-Ssalamah A, Schoppmann SF, et al. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: a retrospective single center analysis. Cancer Biol Ther. 2018;19(3):169–74. https://doi.org/10.1080/15384047.2017.1414759. CrossRefPubMedPubMedCentral

12.

Sun J, Sun Y‑H, Zeng Z‑C, Qin X‑Y, Zeng M‑S, Chen B, et al. Consideration of the role of radiotherapy for abdominal lymph node metastases in patients with recurrent gastric cancer. Int J Radiat Oncol Biol Phys. 2010;77(2):384–91. https://doi.org/10.1016/j.ijrobp.2009.05.019. CrossRefPubMed

13.

Kim M‑S, Yoo SY, Cho CK, Yoo HJ, Yang KM, Kang JK, et al. Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer. J Korean Med Sci. 2009;24(3):488–92. https://doi.org/10.3346/jkms.2009.24.3.488. CrossRefPubMedPubMedCentral

14.

Makiyama A, Sagara K, Kawada J, Kashiwada T, Hosokawa A, Horie Y, et al. A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT). J Clin Oncol. 2018;36(15_suppl):4011. https://doi.org/10.1200/JCO.2018.36.15_suppl.4011. CrossRef

15.

Bang Y‑J. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. J Clin Oncol. 2013;31(4_suppl):11. https://doi.org/10.1200/jco.2013.31.4_suppl.11. CrossRef

16.

Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–53. https://doi.org/10.1016/S1470-2045(17)30111-0. CrossRefPubMed

17.

Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer. 2018;105:41–9. https://doi.org/10.1016/j.ejca.2018.09.024. CrossRefPubMed

18.

Wilke H, Muro K, Van Cutsem E, Oh S‑C, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. https://doi.org/10.1016/S1470-2045(14)70420-6. CrossRefPubMed

19.

Vita FD, Borg C, Farina G, Geva R, Carton I, Cuku H, et al. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. Future Oncol. 2019;15(23):2723–31. https://doi.org/10.2217/fon-2019-0243. CrossRefPubMed

20.

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. ESMO—magnitude of clinical benefit scale V.1.0 questions and answers. ESMO Open. 2016;1(5):e100. https://doi.org/10.1136/esmoopen-2016-000100. CrossRefPubMedPubMedCentral

21.

Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau H‑T, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437–48. https://doi.org/10.1016/S1470-2045(18)30739-3. CrossRefPubMed

22.

Alsina M, Tabernero J, Shitara K, Doi T, Dvorkin M, Mansoor W, et al. Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC). J Clin Oncol. 2019;37(15_suppl):4043. https://doi.org/10.1200/JCO.2019.37.15_suppl.4043. CrossRef

23.

Tohme S, Simmons RL, Tsung A. Surgery for cancer: a trigger for metastases. Cancer Res. 2017;77(7):1548–52. https://doi.org/10.1158/0008-5472.Can-16-1536. CrossRefPubMedPubMedCentral

24.

Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer. 1993;72(5):1631–6. https://doi.org/10.1002/1097-0142(19930901)72:5. CrossRefPubMed

25.

National Cancer Institute. SEER cancer stat facts: stomach cancer. 2019. https://seer.cancer.gov/statfacts/html/stomach.html. Accessed 25 Nov 2019.

26.

Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656–62. https://doi.org/10.1093/annonc/mds104. CrossRefPubMed

27.

Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer—a systematic analysis of data from the literature. J Cancer. 2012;3:137–44. https://doi.org/10.7150/jca.4090. CrossRefPubMedPubMedCentral

28.

Hong SH, Shin YR, Roh SY, Jeon EK, Song KY, Park CH, et al. Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastric Cancer. 2013;16(3):290–300. https://doi.org/10.1007/s10120-012-0182-1. CrossRefPubMed

29.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD‑1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. https://doi.org/10.1056/NEJMoa1500596. CrossRefPubMedPubMedCentral

30.

Shitara K, Bang Y‑J, Iwasa S, Sugimoto N, Ryu M‑H, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30. https://doi.org/10.1056/NEJMoa2004413. CrossRefPubMed

31.

Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821–31. https://doi.org/10.1016/S1470-2045(20)30169-8. CrossRefPubMed

Titel: A case report on the long-term survival of a patient with HER2-positive metastatic gastric adenocarcinoma and a short review of the current literature
Autoren:: MD Hannah Christina Puhr
MD PhD Aysegül Ilhan-Mutlu
Publikationsdatum: 30.09.2020
DOI: https://doi.org/10.1007/s12254-020-00649-2
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Publisher’s Note

Summary

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte